Immuron Limited (ASX:IMC) has requested an immediate trading halt for its securities in order to analyze and interpret CampETEC Hyperimmune Bovine Colostrum (HBC) clinical trial data before making an announcement. The trading halt is expected to remain in place until the announcement is made or until the market opens on 7 October 2024, whichever is earlier.
The trading halt has been requested to allow Immuron to thoroughly analyze the clinical trial data related to CampETEC Hyperimmune Bovine Colostrum. The Company aims to ensure that all necessary information is carefully reviewed before making any announcements. Immuron is committed to providing transparent and accurate updates to the market, and this trading halt is a part of that commitment.
Immuron Limited (ASX:IMC) has requested a trading halt to analyze and interpret CampETEC Hyperimmune Bovine Colostrum clinical trial data before making an announcement. The Company aims to provide the market with carefully considered and accurate information. The trading halt is expected to be lifted after the announcement is made or when the market opens on 7 October 2024. This request reflects Immuron's dedication to ensuring transparent and well-informed communication with the market.